← Eichor
Study identifier: NCT06111950 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Study of the Pathophysiology of RNU4ATAC and RTTN Associated Syndromes

Condition: Taybi Linder Syndrome · Microcephalic Osteodysplastic Primordial Dwarfism Types I and III · Roifman Syndrome  ·  Sponsor: Hospices Civils de Lyon

PhaseNA
Planned participants45
Who can joinAll sexes, N/A to no upper limit
Healthy volunteersYes

About this study

In the human genome, about 750 genes contain one intron excised by the minor spliceosome. These genes are named U12 genes, and these introns, minor or U12 introns. The minor spliceosome comprises its own set of snRNAs, among which U4atac. Its non-coding gene, RNU4ATAC, has been found mutated in Taybi-Linder (TALS), Roifman (RFMN) and Lowry-Wood syndromes (LWS). These rare developmental disorders associate ante- and post-natal growth retardation, microcephaly, skeletal dysplasia, intellectual disability, retinal dystrophy and immunodeficiency. Their physiopathological mechanisms remain unsolved: the number of U12 genes involved, their identity and function, or the cellular mechanisms impacted by the splicing defect, are still unknown. The hypothesis of the study is that U12 genes coding for primary cilia components are particularly sensitive to minor splicing defects caused by RNU4ATAC mutations. Indeed, a child showing signs of TALS but negative for RNU4ATAC was found to carry a homozygous variant in the RTTN gene, coding for the rotatin protein located at the centrosome and the base of the primary cilia and playing a role in maintaining these structures. In addition, bi-allelic RNU4ATAC mutations were identified in five patients presenting with traits suggestive of the Joubert syndrome (JBTS), a well-characterized ciliopathy. These patients also present with traits typical of TALS/RFMN/LWS. To better understand the causes of these pathologies, a cohort of patients with syn…

This description comes directly from the study's public registry record.

Talk to the study team

Sylvie MAZOYER, Dr  ·  04 81 10 65 33  ·  sylvie.mazoyer@inserm.fr

Patrick EDERY, Pr  ·  04 72 12 96 98  ·  charles-patrick.edery@chu-lyon.fr

Always discuss trial participation with your own doctor first.

Locations (6)

Centre de référence des anomalies du développement et syndromes malformatifs du Sud-Ouest Occitanie Réunion, CHU de Bordeaux-GH PellegrinBordeaux, FranceNot Yet Recruiting
Centre de référence anomalies du développement de Lyon, Hôpital Femme Mère EnfantBron, FranceRecruiting
Centre de référence des anomalies du développement et syndromes malformatifs de l'Est, CHU de DIJONDijon, FranceNot Yet Recruiting
Centre de référence des anomalies du développement et syndromes malformatifs de l'inter région Nord-Ouest, Hôpital J de FlandreLille, FranceNot Yet Recruiting
Unité Fonctionelle d'embryo-fœtopathologie, Hôpital Necker-Enfants MaladesParis, FranceNot Yet Recruiting
Centre de référence des anomalies du développement et syndromes malformatifs de l'Ouest, Hôpital SudRennes, FranceNot Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06111950